FDA’s Post-Marketing Efforts Criticized

NYT’s story’s lede:

Disorganization, bureaucratic infighting and an inability to force drug makers to conduct needed safety tests have undercut efforts at the Food and Drug Administration to uncover drug dangers, government auditors say.

And a quote from Curt Furberg, who, though the story doesn’t note it, has also served as a paid plaintiffs’ expert in pharmaceutical litigation:

“I think the report is terrific,” said Dr. Curt Furberg, a professor of public health sciences at Wake Forest University School of Medicine. “The F.D.A.’s office of drug safety has absolutely no clout and no money, and the report showed that.”

The Post has a similar piece.

(I represented pharmaceutical companies when in practice and continue to have a small consulting role.)